![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.557, 2008-01, pp. : 9-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Botulinum toxin A eases chronic migraine
Inpharma, Vol. 1, Iss. 1656, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Heads up on botulinum toxin's use in migraine
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 560, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Botulinum toxin type A for the treatment of migraine
Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Levetiracetam may be an appropriate prophylactic treatment for paediatric migraine
Inpharma, Vol. 1, Iss. 1434, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Triptan use in migraine curbed by cost
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 471, 2005-01 ,pp. :